肝硬化門靜脈高壓伴自發(fā)性門體分流的診治現(xiàn)狀與展望
摘要: 肝硬化是各種慢性肝病的終末階段,主要的臨床表現(xiàn)為門靜脈高壓,其發(fā)生可導(dǎo)致自發(fā)性門體分流(SPSS)。SPSS在臨床上多見,并且與患者預(yù)后息息相關(guān)。本文總結(jié)了近年來研究肝硬化門靜脈高壓伴SPSS的臨床意義、研究中所存爭(zhēng)議、當(dāng)前治療現(xiàn)狀以及未來展望與挑戰(zhàn),為門靜脈高壓的規(guī)范化診治提供參考。
關(guān)鍵詞: 肝硬化; 高血壓, 門靜脈; 自發(fā)性門體分流
基金項(xiàng)目: 西安市科技計(jì)劃項(xiàng)目(23YXYJ0180); 西安醫(yī)學(xué)院創(chuàng)新團(tuán)隊(duì)(2021TD15); 佑安肝病感染病專科醫(yī)療聯(lián)盟科研專項(xiàng)基金(LM202028)
Diagnosis and treatment of cirrhotic portal hypertension with spontaneous portosystemic shunt: Current statusand prospects
CHEN Yaxin 1,2 , GUO Wen 1,2 , LIU Kaige 1 , LI Qian 1 , ZHANG Mingxin 1
1. Department of Gastroenterology, The First Affiliated Hospital of Xi’an Medical College, Xi’an 710077, China; 2. GraduateSchool of Xi’an Medical University, Xi’an 710021, China
Corresponding author: ZHANG Mingxin, zmx3115@xiyi.edu.cn (ORCID: 0000-0002-3945-3387)
Abstract: Liver cirrhosis is the terminal stage of various chronic liver diseases, with the main clinical manifestation of portalhypertension, which can lead to spontaneous portosystemic shunt (SPSS). SPSS is very common in clinical practice and is closelyassociated with the prognosis of patients. This article summarizes the recent studies in the clinical significance of cirrhotic portalhypertension with SPSS, the controversies in studies, and the current status and future prospects and challenges of treatment, inorder to provide a reference for the standardized diagnosis and treatment of portal hypertension.Key words: Liver Cirrhosis; Hypertension, Portal; Spontaneous Portosystemic ShuntResearch funding: Xi’an Science and Technology Plan Project (23YXYJ0180); The Innovation Team of Xi’an MedicalUniversity (2021TD15); Youan Specialist Medical Alliance for Liver and Infectious Diseases Special Fund (LM202028)
在肝硬化患者中,門靜脈高壓可導(dǎo)致自發(fā)性門體分流(spontaneous portal system shunt,SPSS)發(fā)生。(剩余17727字)
- 四十華誕 春華秋實(shí)...
- 慢性乙型肝炎功能性治愈不是夢(mèng)...
- 乙型肝炎功能性治愈新藥: 聚焦...
- 慢性乙型肝炎功能性治愈離完全治...
- 乙型肝炎病毒基因整合對(duì)功能性治...
- 晚期肝細(xì)胞癌免疫靶向聯(lián)合轉(zhuǎn)化序...
- 《2024年亞太肝病學(xué)會(huì)推薦意...
- 恩替卡韋與富馬酸丙酚替諾福韋初...
- 低病毒載量HBeAg陰性不確定...
- HBV相關(guān)慢加急性肝衰竭恢復(fù)期...
- 不同亞型非酒精性脂肪性肝病患者...
- 立體定向放療聯(lián)合信迪利單抗和貝...
- 原發(fā)性肝癌干預(yù)前并發(fā)肝性胸腔積...
- 415例原發(fā)性肝癌中醫(yī)證候分布...
- 索拉非尼和多納非尼對(duì)大鼠體內(nèi)艾...
- 膽汁淤積性肝病患兒的維生素D水...
- 人工肝治療肝衰竭患者血紅蛋白水...
- 胸腺基質(zhì)淋巴細(xì)胞生成素在對(duì)乙酰...
- 膽囊切除術(shù)后原發(fā)性膽總管結(jié)石復(fù)...
- 以肝脾腫大為首發(fā)表現(xiàn)的POEM...
- 健康相關(guān)生活質(zhì)量評(píng)估在慢性乙型...
- 機(jī)器學(xué)習(xí)在慢性丙型肝炎診療中的...
- 瑞美替羅(Resmetirom...
- 脂肪因子與代謝相關(guān)脂肪性肝病及...
- 動(dòng)力蛋白相關(guān)蛋白1(Drp1)...
- 脂肪因子Chemerin與肝纖...
- 中藥逆轉(zhuǎn)肝纖維化的分子機(jī)制...
- 肝硬化門靜脈高壓伴自發(fā)性門體分...
- 肝靜脈剝奪術(shù)的研究進(jìn)展...
- 胰膽管合流異常的研究進(jìn)展...
- The New England...
- Journal of Hepa...
- 《臨床肝膽病雜志》入選新華網(wǎng)“...
- 《臨床肝膽病雜志》入選“中國科...